Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease

Medical Hypotheses

Volumn 63, Issue 2, 2004, Pages 308-321

  Shen, Z X ^a  

^a 55427 5011 ^*  (United States)

Author keywords

AChE, Acetylcholinesterase; AD, Alzheimer's disease; BChE, Butyrylcholinesterase; ChEs, Cholinesterases; NFT, Neurofibrillary tangle; SP, Senile plaque

Indexed keywords

ACETYLCHOLINESTERASE; BRAIN ENZYME; MEMBRANE ENZYME; MEMBRANE PROTEIN;

ALZHEIMER DISEASE; CYTOPATHOLOGY; DISEASE ASSOCIATION; ENCEPHALITIS; ENZYME ACTIVITY; ENZYME METABOLISM; GENETIC ASSOCIATION; HUMAN; HYPOTHESIS; IMMUNOREACTIVITY; INTRACELLULAR MEMBRANE; MOLECULAR DYNAMICS; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; TAUOPATHY;

ANIMALIA;

EID: 3242782586     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.02.031     Document Type: Article

References (103)

1. Alzheimer A. A characteristic disease of the cerebral cortex. Schultze E., Snell O. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche medizin. 1907;146-148 Georg Relmer, Berlin
2. Barco A., Pittenger C., Kandel E.R. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin. Ther. Targets. 7:2003;101-114
3. Forstl H. Alzheimer's disease: the size of the problem, clinical manifestation and heterogeneity. J. Neural. Transm. (Suppl.). 54:1998;1-8
4. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163:2000;495-529
5. Volicer L., Crino P.B. Involvement of free radicals in dementia of the Alzheimer type: a hypothesis. Neurobiol. Aging. 11:1990;567-571
6. Roses A.D. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J. Neuropathol. Exp. Neurol. 53:1994;429-437
7. Hardy J.A., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356
8. Tolnay M., Probst A. Tau protein pathology in Alzheimer's disease and related disorders. Neuropathol. Appl. Neurobiol. 25:1999;171-187
9. McCaddon A., Kelly C.L. Alzheimer's disease: a 'cobalaminergic' hypothesis. Med. Hypotheses. 37(3):1992;161-165
10. Rogers J., Webster S., Lue L.F., et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging. 17:1996;681-686
11. Amenta F., Parnetti L., Callai V., Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precusors. Ineffective treatments or inappropriate approaches? Mech. Aging Dev. 122:2001;2025-2040
12. Birks J.S., Melzer D., Beppu H. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst. Rev. 4:2000;CD001190
13. Davies P. A very incomplete comprehensive theory of Alzheimer's disease. Ann. N. Y. Acad. Sci. 924:2000;8-16
14. Lippa G.F., Saunders A.M., Smith J.M., et al. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology. 46:1996;406-412
15. Bayer T.A., Wirths O., Majtënyi K., et al. Key factors in Alzheimer's disease: β-amyloid precusor protein processing, metabolism and intraneuronal transport. Brain Pathol. 11:2001;1-11
16. Pfeifer M., Boncristiano S., Bondolfi L., et al. Cerebral hemorrhage after passive anti-amyloid-beta immunotherapy. Science. 298:2002;1379-1380
17. De Kosky S.T. Epidemiology and pathophysiology of Alzheimer's disease. Clin. Cornerstone. 3(4):2001;15-26
18. McCaddon A., Regland B., Hudson P., Davies G. Functional vitamin B (12) deficiency and Alzheimer disease. Neurology. 58:2002;1395-1399
19. Deana R., Vincenti E., Deana A.D. Levels of neurotransmitters in brain of vitamin B12 deficient rats. Int. J. Vitam. Nutr. Res. 47:1977;119-122
20. Knight J.A. Free radicals: their history and current status in aging and disease. Ann. Clin. Lab. Sci. 28(6):1998;331-346
21. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron. 35:2002;419-432
22. Mesulam M.M. Neuroplasticity falure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron. 24:1999;521-529
23. De Ferrari G.V., Inestrosa N.C. Wnt signaling function in Alzheimer's disease. Brain Res. Rev. 33:2000;1-12
24. Chen M., Fernandez H.L. Where do Alzheimer's plaques and tangles come from? Aging-induced protein degradation inefficiency. Front Biosci. 6:2001;e1-e11
25. Braak E., Griffing K., Arai K., et al. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur. Arch. Psychiatry Clin. Neurosci. 249(Suppl 3):1999;14-22
26. Shen Z.X. Acetylcholinesterase provides deeper insight into Alzheimer's disease. Med. Hypotheses. 43:1994;21-30
27. 4) acetylcholinesterase: structure, localization, and physiological regulation. J. Neurochem. 66:1996;1335-1346
28. Inestrosa N.C., Alvarez A., Perez C.A., et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 16(4):1996;881-891
29. Kasa P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 52:1997;511-535
30. Mesulam M.M. neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. Giacobini E. Cholinesterases and cholinesterase inhibitors. 1st ed.:2000;121-138 Martin Dunitz Ltd., London
31. Alvarez A., Opazo C., Alarcon R., Inestrosa N.C. Acetylcholinesterase promotes the aggregation of amyloid-β-peptide fragmemts by forming a complex with the growing fibrils. J. Mol. Biol. 272:1997;348-361
32. Munoz F.J., Inestrosa N.C. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of A-beta-peptide and the AChE concentration present in the complexes. FEBS Lett. 450(3):1999;205-209
33. Alvarez A., Alarcon R., Opazo C., et al. Stable complexes involving acetylcholinesterase and amyloid-β-peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci. 18(9):1998;3213-3223
34. Inestrosa N.C., Alvarez A., Godoy J., et al. Acetylcholinesterase- amyloid-β-peptide interaction and Wnt signaling involvement in Aβ neurotoxicity. Acta Neurol. Scand. (Suppl 176):2000;53-59
35. Games D., Khan K.M., Sorian F.G., et al. Lack of Alzheimer pathology after β-amyloid protein injections in rat brain. Neurobiol. Aging. 13:1992;569-576
36. De Ferrari G.V., Canales M.A., Shin I., et al. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry. 40:2001;10447-10457
37. Linn R.T., Wolf P.A., Bachman D.L., et al. The 'preclinical phase' of probable Alzheimer's disease. Arch. Neurol. 52:1995;485-490
38. Scahill R.I., Schott J.M., Stevens J.M., et al. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc. Natl. Acad. Sci. USA. 99(7):2002;4703-4707
39. Namba H., Iyo M., Shinotoh H., et al. Preserved acetylcholinesterase activity in aged cerebral cortex. Lancet. 351:1998;881-882
40. Kuhl D.E., Koeppe R.A., Minoshima S., et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology. 52:1999;691-699
41. Shinotoh H., Namba H., Fukushi K., et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a position emission tomography study. Ann. Neurol. 48(2):2000;194-200
42. Wu D., Hersh L.B. Choline acetyltransferase: celebrating its fiftieth year. J. Neurochem. 62:1994;1653-1663
43. Chatonnet A., Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 260:1989;625-634
44. Cooper J.R., Bloom F.E., Roth R.H. Acetylcholine. The biochemical basis of neuropharmacology. 7th ed.:1996;194-225 Oxford University Press, New York
45. Silver A. The biology of cholinesterase: frontiers of biology. 1974;Elsevier/North-Holland, Amsterdam
46. Grisaru D., Sternfeld M., Eldor A., Glick D., Soreq H. Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem. 264:1999;672-686
47. Lockridge O., Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurol. Toxicol. 21(1-2):2000;113-126
48. Appleyard M.A. Secreted acetylcholinesterase: non-classical aspects of a classical enzyme. Trends Neurosci. 15(12):1992;485-490
49. Taylor P., Luo Z.D., Camp S. The genes encoding the cholinesterases: structure, evolutionary relationships and regulation of their expression. Giobelini E. Cholinesterases and cholinesterase inhibitors. 1st ed.:2000;63-79 Martin Dunitz Ltd., London
50. Massoulié J. Molecular forms and anchoring of acetylcholinesterae. Giacobini E. Cholinesterases and cholinesterase inhibitors. 1st ed.:2000;81-101 Martin Dunitz, London
51. Flores-Flores C., Martinez-Martinez A., Munoz-Delgado E., Vidal C.J. Conversion of acetylcholinesterase hydrophilic tetramers into amphilic dimers and monomers. Biochem. Biophys. Res. Commun. 219(1):1996;53-58
52. Nalivaeva N.N., Turner A.J. Post-translational modifications of proteins: acetylcholinesterase as a model system. Proteomics. 1:2001;735-747
53. Soreq H., Seidman S. Acetylcholinesterase - new roles for an old actor. Nat. Rev. Neurosci. 2(4):2001;294-302
54. Balasubramanian A.S. Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase. Neurochem. Res. 26(4):2001;453-456
55. Greenfield S.A. A noncholinergic action of acetylcholinesterase (AChE) in the brain: from neuronal secretion to the generation of movement. Cell. Mol. Neurobiol. 11(1):1991;55-77
56. Whyte K.A., Greenfield S.A. Effects of acetylcholinesterase and butyrylcholinesterase on cell survival, neurite outgrowth, and voltage-dependent calcium currents of embryonic ventral mesencephalic neurons. Exp. Neurol. 184:2003;496-509
57. Layer P.G., Willbold E. Novel functions of cholinesterases in development, physiology and disease. Prog. Histochem. Cytochem. 29:1995;1-94
58. Munoz F.J., Aldunate R., Inestrosa N.C. Peripheral binding site is involved in the neurotrophic activity of acetylcholinesterase. NeuroReport. 10:1999;3621-3625
59. Gupta R.C., Milatovic D., Dettbarn W.D. Depletion of energy metabolites following acetylcholinesterase inhibitor-induced status epilepticus: protection by antioxidants. Neurotoxicology. 22(2):2001;271-282
60. Behra M., Cousin X., Bertrand C., et al. Acetylcholinesterase is required for neuronal and muscular development in the zebrafish embryo. Nat. Neurosci. 5(2):2002;111-118
61. Xie W., Stribley J.A., Chatonnet A., et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J. Pharmacol. Exp. Therap. 293(3):2000;896-902
62. Duysen E.G., Stribley J.A., Fry D.L., et al. Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Dev. Brain Res. 137:2002;43-54
63. Beeri R., Andres C., Lev-Lehman E., et al. Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr. Biol. 5(9):1995;1063-1071
64. Sternfeld M., Patrick J.D., Soreq H. Position effect variegations and brain-specific silencing in transgenic mice overexpressing human acetylcholinesterase variant. J. Physiol. (Paris). 92:1998;249-255
65. Beeri R., Leovere N., Mervis R., et al. Enhanced hemicholinium binding and attenuated dendrite branching in cognitively impaired AChE-transgenic mice. J. Neurochem. 69:1997;2441-2451
66. Masters C.L., Beyreuther K. Protein abnormalities in neurofibrillary tangles: their relationship to the extra-cellular amyloid deposits of the A4 protein in Alzheimer's disease. Alzheimer's disease: advances in basic research and therapies. 1989;235-268 Center for Brain Sciences and Metabolism, Charitable trust, Cambridge
67. McGeer E.G., McGeer P.L., Kamo H., et al. Cortical metabolism, acetylcholinesterase staining and pathological changes in Alzheimers disease. Can. J. Neurol. Sci. 13:1986;511-516
68. Ulrich J., Meier-Ruge W., Probst A., et al. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol. 80:1990;624-628
69. Beach T.G., Sue L.I., Scott S., et al. Neurofibrillary tangles are constant in aging human nucleus basalis. Alzheimer's Rep. 1(6):1998;375-380
70. Geula C., Mesulam M.M., Saroff D.W., et al. relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J. Neuropathol. Exp. Neurol. 57(1):1998;63-75
71. Beach T.G., Honer W.G., Hughes L.H., et al. Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease? Acta Neuropathol. 93(2):1997;146-153
72. Bornemann K.D., Staufenbiel M. Transgenic mouse models of Alzheimer's disease. Ann. N. Y. Acad. Sci. 908:2000;260-266
73. Saez-Valero J., Small D.H. Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease. J. Alzheimer's Dis. 3:2001;323-328
74. Saxena A., Ashani Y., Raveh L., Stevenson D., Patel T., Doctor B.P. Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol. Pharmacol. 53:1998;112-122
75. Mimori Y., Nakamura S., Yukawa M. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behav. Brain Res. 83:1997;25-30
76. Fodero L.R., Saez-Valero J., McLean C.A., et al. Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. J. Neurochem. 81(3):2002;441-448
77. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp. Gerontol. 35:2000;1363-1372
78. Toledano A., Alvarez M.I., Rivas L., Lacruz C., Martinez-Rodriguez R. Amyloid precursor proteins in the cerebellar cortex of Alzheimer's disease patients devoid of cerebellar β-amyloid deposits: immunocytochemical study of five cases. J. Neural. Transm. 106:1999;1151-1169
79. Wirths O., Multhaup G., Czech C., et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 306:2001;116-120
80. Liu F., Zaidi T., Iqbal K., et al. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett. 512:2002;101-106
81. Gomez-Ramos P., Mufson E.J., Moran M.A. Ultrastructural localization of acetylcholinesterase in neurofibrillary tangles, neuropil threads and senile plaques in aged and Alzheimer's brain. Brain Res. 569:1992;229-237
82. Gomez-Ramos P., Moran M.A. Ultrastructural aspects of neurofibrillary tangle formation in aging and Alzheimer's disease. Microsc. Res. Technol. 43:1998;49-58
83. Hall G.F., Chu B., Lee G., Yao J. Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease. J. Cell Sci. 113:2000;1373-1387
84. Gray E.G., Paula-Barbosa M., Roher A. Alzheimer's disease: paired helical filaments and cytomembranes. Neuropathol. Appl. Neurobiol. 13:1987;91-110
85. Davey G.P., Peuchen S., Clark J.B. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J. Biol. Chem. 273:1998;12753-12757
86. Stieber A., Mourelatos Z., Gonatas N.K. In Alzheimer's disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic. Am. J. Pathol. 148:1996;415-426
87. Ojaimi J., Byrne E. Mitochondrial function and Alzheimer's disease. Biol. Signals Recept. 10(3-4):2001;254-262
88. Gomez-Ramos P., Moran M.A. Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer' disease patients. Mol. Chem. Neuropathol. 30(3):1997;161-173
89. Pettergrew J.W., Panchalingam K., Hamilton R.L., McClure R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 26(7):2001;771-782
90. Perrier A.L., Massoulie J., Krejci E. PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron. 33:2002;275-285
91. Morimoto A., Irie K., Murakami K., et al. Aggregation and neurotoxicity of mutant amyloid beta (A beta) peptides with proline replacement: importance of tau formation at positions 22 and 23. Biochem. Biophys. Res. Commun. 295(2):2002;306-311
92. Pelech S.L. Networking with proline-directed protein kinases implicated in tau phosphorylation. Neurobiol. Aging. 16(3):1995;247-261
93. Lucas J.J., Hernandez F., Gomez-Ramos P., et al. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20:2001;27-39
94. Couderc R. Search of biological markers of Alzheimer's disease. Ann. Biol. Clin. (Paris). 58(5):2000;581-593
95. Koistinaho M., Ort M., Cimadevilla J.M., et al. Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. USA. 98:2001;14675-14680
96. Perry R.H., Blessed G., Perry E.K., Tomlinson B.E. Histochemical observations of cholinesterase activities in the brains of elderly normal and demented (Alzheimer-type) patients. Age Ageing. 9:1980;9-16
97. Billingsley M.L., Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 323:1997;577-591
98. Gotz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276:2001;529-534
99. Lewis J., Dickson D.W., Lin W.L., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:2001;1487-1491
100. Mesulam M.M., Brimijion S., Geula C. neurofibrillary tangles have no obligatory predilection for acetylcholinesterase-rich neurons. Neurobiol. Aging. 15(5):1994;615-619
101. Geula C., Mesulam M.M. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis. Associ. Disord. 9(2):1995;23-28
102. Masson P., Schopfer L.M., Bartels C.F., et al. Substrate activation in acetylcholinesterase induced by low pH or mutation in the pi-cation subsite. Biochem. Biophys. Acta. 1594(2):2002;313-324
103. Bissette G., Seidler F.J., Nemeroff C.B., Slotkin T.A. High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. Ann. N. Y. Acad. Sci. 777:1996;197-204